Gram positive and gram negative coverage Streptococcus species (incl some Enterococci), Listeria, H. flu, ... compared to meropenem Risk of seizures more common in renal failure Meropenem (IV – Merrem) ... strep and Enterococcus faecalis TETRACYCLINES - … Piperacillin-tazobactam is a broad spectrum antibiotic with excellent coverage against anaerobes and ampicillin-susceptible E. faecalis. Meropenem showed strong activity against all tested organisms with >15-mm mean inhibition halos. Excipients with known effect: Each 500 mg vial contains 104 mg sodium carbonate which equates to approximately 2 mEq of sodium (approximately 45 mg). Tobramycin and daptomycin in combination had moderate broad-spectrum activity with 8- to 14-mm mean inhibition halos. Imipenem, Meropenem, Doripenem special coverage. Generally, meropenem is two-to 16-fold more active than. Aztreonam (a monobactam) Ciprofloxacin (Resistance is increasing) & Levofloxacin. Identification of enterococci to the species level was based on a series of conventional biochemical tests. Proteus mirabilis H. influenzae E. coli The combination meropenem-vaborbactam has not been evaluated in vitro against gram-posi-tive organisms, but retains the gram-positive activity of meropenem; however, it has limited coverage against methicillin-resistant Staphylo-coccus aureus (MRSA), Enterococcus faecalis, and Enterococcus faecium [23–25]. Enterococcus faecalis is the most common human pathogen, but Enterococcus faecium has become increasingly prevalent in hospital-acquired infections. Enterococcus is a topic covered in the Johns Hopkins ABX Guide.. To view the entire topic, please sign in or purchase a subscription.. Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Enterococcus faecalis strains, 1 of 1 Klebsiella pneumoniae strain, and 1 of 1 Escherichia ... Key words： Meropenem, 3g/day administration, Severe pneumonia ... from 1g to 3g for severe refractory infections, allowing coverage by the national health insurance system. They have poor coverage of MRSA and enterococcal infections because of their aforementioned intrinsic resistance. As you know meropenem has little effect on E. faecium, and the MICs against E. faecalis tend to be higher than for other streptococci (e.g. Although imipenem has in vitro activity against Enterococcus faecalis and Food and Drug Administration-approved indications for treatment of infections caused by this microorganism, there are no NCCLS guidelines for susceptibility testing of imipenem versus enterococci. Dual beta-lactam therapy can be appropriate, however instances where this is the case are relatively few and occur fairly infrequently. In this article, an infectious diseases and antimicrobial stewardship pharmacist identifies several examples of when dual beta-lactam therapy can be appropriate. Coverage E. coli, P. mirabilis, K. pneumonia, S. aureus, Enterococcus faecalis Adverse effects rash, GI upset (diarrhea, more with q8h dosing ~25% formulations than with q12h formulations ~10% ) (Other less common effects: eosinophilia, leukopenia and thrombocytosis; superinfections resulting in … Comparative in-vitro activity of meropenem against selected pathogens from hospitalized patients in the Netherlands. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding-protein (PBP) targets. Meropenem is metabolised by hydrolysis of the beta-lactam ring generating a microbiologically inactive metabolite. Stenotrophomonas maltophilia, Enterococcus faecium and methicillin-resistant staphylococci have been found to be resistant to meropenem.